e-Therapeutics has begun a randomized, double-blind, controlled Phase IIb trial of ETS6103 in major depressive disorder. The trial is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centers with a history of involvement in depression studies in the Glasgow area of Scotland. ETS6103 is a controlled-release formulation of tramad...